Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Misses on Revenue, Stock Up 3.16%

Corvus Pharmaceuticals reported an EPS of $-0.14, which met expectations, but did not provide revenue figures. Despite the lack of revenue data, the stock reacted positively, increasing by 3.16%. This suggests that investors may have had lower expectations or are optimistic about future developments.